Zobrazeno 21 - 30
of 32
pro vyhledávání: '"Allison Berger"'
Autor:
Khristofer Garcia, Erik Koenig, Hugues Bernard, Xiaozhen Liu, Eric S. Lightcap, Allison Berger, Jonathan L. Blank, David C. Bouck, Mike Kuranda
Publikováno v:
Cancer Research. 77:1423-1423
Platins are one of the most widely used classes of chemotherapeutic drugs. Although used as part of first-line standard of care regimens for advanced non-small cell lung cancer (NSCLC), their effectiveness remains limited, with a 5-year survival rate
Autor:
Allison Berger, Darshan S. Sappal, Kenichi Iwai, Yuko Ishii, Neil F. Bence, Jennifer Duffy, Eric S. Lightcap, Jeffrey Ciavarri, Marc L. Hyer, Akihiro Ohashi, Jessica Huck, Judy Qiuju Shi, Tary Traore, Michael Milhollen, Claudia Rabino
Publikováno v:
Cancer Research. 76:3719-3719
Radiation therapy, as a primary therapy or as a combination partner, is used in half of all worldwide cancer treatments. Research is ongoing to identify agents which potentiate the effects of ionizing radiation (IR) in tumor cells. Because IR causes
Autor:
Xiaozhen J. Liu, Eric S. Lightcap, Allison Berger, Khristofer Garcia, Jonathan L. Blank, Erik Koenig, David C. Bouck, Mike Kuranda, Hugues Bernard
Publikováno v:
Molecular Cancer Therapeutics. 14:C55-C55
Platinum-based therapies, both cisplatin and carboplatin, are utilized as part of first-line standard of care regimens for advanced non-small cell lung cancer (NSCLC), but overall response rate and overall survival remain limited, with a 5-year survi
Autor:
Michael P. Thomas, Syamala Bandi, Xiaozhen J. Liu, Katherine Cosmopoulos, Eric S. Lightcap, Peter G. Smith, Raymond W. Liu, Khristofer Garcia, Michael D. Pickard, Mike Kuranda, Greg Hather, Allison Berger, David C. Bouck, Jonathan L. Blank
Publikováno v:
Molecular Cancer Therapeutics. 12:B92-B92
MLN4924 is an investigational small molecule inhibitor of the Nedd8-activating enzyme (NAE) currently in Phase 1 clinical trials. MLN4924 induces DNA damage via rereplication in most cell lines. This distinct mechanism of DNA damage may affect its ab
Autor:
Hugues Bernard, James J. Garnsey, Erik Koenig, Ben Amidon, Allison Berger, Eric S. Lightcap, Nibedita Chattopadhyay
Publikováno v:
Molecular Cancer Therapeutics. 12:B156-B156
The investigational proteasome inhibitor ixazomib (MLN2238) inhibits cell growth in a broad panel of solid tumor and hematological cell lines when tested in vitro. In contrast, antitumor activity in xenograft-bearing mice is model-dependent, with som
Autor:
Mark R. Conaway, Susan C. Modesitt, Jonghoon Park, Jennifer Bryant, Peter G. Smith, Michael Milhollen, Allison Berger, Amir A. Jazaeri, Anindya Dutta, Etsuko Shibata
Publikováno v:
Cancer Research. 73:3380-3380
Purpose: The objective of this investigation was to evaluate the preclinical activity of MLN4924, an investigational inhibitor of the NEDD8-activating enzyme, against chemoresistant and chemosensitive ovarian cancer cells. ExperimentalDesign: Efficac
Autor:
Yu Yang, Christopher Tsu, Michael D. Sintchak, Allison Berger, Lawrence Dick, Khristofer Garcia, Jie Yu, Paul Hales, Yueying Kao, Frank J. Bruzzese, Jefrey P Ciavarri, Jonathan L. Blank, Paul E. Fleming, Erik Kupperman, Jane Liu, Bret Bannerman, Mark Manfredi, Edmund Lee, Michael Fitzgerald
Publikováno v:
Molecular Cancer Therapeutics. 10:C99-C99
Bortezomib (Velcade®) is a proteasome inhibitor that has been approved by the U.S. Food and Drug Administration for the treatment of patients with multiple myeloma or relapsed mantle cell lymphoma. It is currently available in more than 90 countries
Autor:
Bret Bannerman, Mark Manfredi, Kristen Bano, Yu Yang, Brad Stringer, Steve Blakemore, Jill Donelan, Nibedita Chattopadhyay, Allison Berger
Publikováno v:
Cancer Research. 71:2828-2828
The successful development of VELCADE® (bortezomib) for multiple myeloma and previously treated mantle cell lymphoma has validated the proteasome as a therapeutic target for hematological malignancies. The investigational drug MLN9708 is a modified
Autor:
Peter G. Smith, James J. Garnsey, Allison Berger, George Mullligan, Bradley Stringer, Michael D. Pickard, Jie Yu, Kristin E. Burke, Doug Bowman, Alice McDonald, Mark D. Fleming
Publikováno v:
Clinical Cancer Research. 16:A31-A31
The novel small molecule MLN4924 is an inhibitor of the NEDD8 activating enzyme (NAE) and is currently in Phase I trials. As part of the ubiquitin-proteasome system, NAE is required for activity of cullin ring ligases (CRLs), a category of ubiquitin
Autor:
Sai M. Pulukuri, Derek Liqiang Tou, Allison Berger, Lilli Petruzzelli, Peter G. Smith, Mark Manfredi, Michael D. Pickard, Tary Traore
Publikováno v:
Molecular Cancer Therapeutics. 8:B189-B189
MLN4924 is a novel, small molecule inhibitor of Nedd8-activating enzyme (NAE) that is currently in Phase I clinical trials in hematologic malignancies. We have previously described the pre-clinical anti-tumor activity of MLN4924 in human xenograft mo